Skip to main content
. 2021 May 23;13(11):2553. doi: 10.3390/cancers13112553

Figure 4.

Figure 4

Kaplan–Meier figures with overall survival (OS) and disease-free survival (DFS) in patients with TSCC/BOTSCC (A,B). Patients with HPV DNA positive and p16 positive (HPV+/p16+) TSCC/BOTSCC had a significantly better OS and DFS, respectively (A,B, respectively), as compared to patients with HPV DNA negative and p16 negative TSCC/BOTSCC (log rank: p < 0.0001 and p < 0.0001, respectively). However, patients with p16 positive but HPV negative (HPV−/p16+) TSCC/BOTSCC presented an intermediate OS and DFS compared to patients with double positive or double negative HPV/p16 status. (HPV+p16+ vs. HPV−p16+ (log rank test): OS: p = 0.047; DFS: p = 0.1, and HPV−p16+ vs. HPV−p16− (log rank test): OS: p = 0.001; DFS: p = 0.05).